T
Toshinobu Hayashi
Researcher at Fukuoka University
Publications - 31
Citations - 201
Toshinobu Hayashi is an academic researcher from Fukuoka University. The author has contributed to research in topics: Chemotherapy-induced nausea and vomiting & Antiemetic. The author has an hindex of 6, co-authored 22 publications receiving 148 citations.
Papers
More filters
Journal ArticleDOI
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Kenichi Suzuki,Takeharu Yamanaka,Hiroya Hashimoto,Yoshihisa Shimada,K. Arata,Reiko Matsui,K. Goto,Tomomi Takiguchi,Fumiyoshi Ohyanagi,Y. Kogure,Naoyuki Nogami,Masahiko Nakao,Kentaro Takeda,Koichi Azuma,Seisuke Nagase,Toshinobu Hayashi,Kimiko Fujiwara,T. Shimada,Nobuhiko Seki,Nobuyuki Yamamoto +19 more
TL;DR: The present study did not show the superiority of palonosetron when compared with granisetron in the triplet regimen regarding the primary end point, which was complete response at the 0-120 h period.
Journal ArticleDOI
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.
Daiki Tsuji,Mari Yokoi,Kenichi Suzuki,Takashi Daimon,Masahiko Nakao,H. Ayuhara,Y. Kogure,K Shibata,Toshinobu Hayashi,Keita Hirai,Kazuyuki Inoue,Toshihiro Hama,K Takeda,Makoto Nishio,Kunihiko Itoh +14 more
TL;DR: Investigation of the potential roles of ABCB1 and ABCG2 polymorphisms in antiemetic treatment resistance in patients with cancer previously enrolled in a randomized controlled trial revealed that they were significant predictors of CR.
Journal ArticleDOI
Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.
Hironobu Hashimoto,Takeharu Yamanaka,Yasuhiro Shimada,Koji Arata,Reiko Matsui,Koichi Goto,Tomomi Takiguchi,Fumiyoshi Ohyanagi,Y. Kogure,Naoyuki Nogami,Masahiko Nakao,Koji Takeda,Kanako Azuma,Seisuke Nagase,Toshinobu Hayashi,Kimiko Fujiwara,Toshikazu Shimada,Nobuhiko Seki,Kenichi Suzuki,Nobuyuki Yamamoto +19 more
TL;DR: This study compared the efficacy of two 5-HT3drugs, PALO and GRA, in the triplet regimen to detect a 10% improvement in the overall response at the overall (0-120 hours) phase.
Journal ArticleDOI
A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Hirotoshi Iihara,Hirotoshi Iihara,Mototsugu Shimokawa,Toshinobu Hayashi,Hitoshi Kawazoe,Toshiaki Saeki,Keisuke Aiba,Kazuo Tamura +7 more
TL;DR: For patients receiving carboplatin-based chemotherapy, triple antiemetic therapy with 5-hydroxytryptamine-3 receptor antagonist, dexamethasone, and neurokinin-1 receptor antagonist should be given prophylactically regardless of risk factor status.
Journal ArticleDOI
Antithrombin gamma attenuates macrophage/microglial activation and brain damage after transient focal cerebral ischemia in mice.
Takafumi Nakano,Yoshihiko Nakamura,Keiichi Irie,Shinobu Okano,Mayuka Morimoto,Yuta Yamashita,Tomohiro Kozako,Toshinobu Hayashi,Shin-ichiro Honda,Koichi Matsuo,Hidetoshi Kamimura,Hiroyasu Ishikura,Takashi Egawa,Kenichi Mishima +13 more
TL;DR: Treatment with AT showed neuroprotective effects via anticoagulation actions, as well as direct anti-inflammatory effects on macrophage/microglial activation in mice subjected to middle cerebral artery occlusion, suggesting that AT may be a useful new therapeutic option for cerebral ischemia.